Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


03.06.2019

1 Am J Clin Oncol
2 Ann Oncol
1 Ann Surg Oncol
6 BMC Cancer
1 Br J Cancer
3 Breast Cancer
3 Breast Cancer Res
9 Breast Cancer Res Treat
4 Breast J
1 Cancer Lett
2 Clin Cancer Res
2 Eur J Surg Oncol
1 J Natl Cancer Inst
2 Lancet Oncol
3 Pathology
1 PLoS Genet
2 PLoS One
2 Proc Natl Acad Sci U S A
3 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol


  1. Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI): Erratum.
    Am J Clin Oncol. 2019;42:545-542.
    PubMed     Text format    


    Ann Oncol

  2. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019 Apr 9. pii: 5435960. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. OLIVEIRA M, Saura C, Nuciforo P, Calvo I, et al
    FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Ann Oncol. 2019 May 30. pii: 5506637. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  4. ZHU S, Wu J, Huang O, He J, et al
    Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample.
    Ann Surg Oncol. 2019 May 29. pii: 10.1245/s10434-019-07480.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:517.
    PubMed     Text format     Abstract available

  6. HOLLECZEK B, Stegmaier C, Radosa JC, Solomayer EF, et al
    Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany.
    BMC Cancer. 2019;19:520.
    PubMed     Text format     Abstract available

  7. KIKUCHI-KOIKE R, Nagasaka K, Tsuda H, Ishii Y, et al
    Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
    BMC Cancer. 2019;19:521.
    PubMed     Text format     Abstract available

  8. PLAZA-DIAZ J, Alvarez-Mercado AI, Ruiz-Marin CM, Reina-Perez I, et al
    Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
    BMC Cancer. 2019;19:495.
    PubMed     Text format     Abstract available

  9. AL-SALAM S, Sudhadevi M, Awwad A, Al Bashir M, et al
    Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:135.
    PubMed     Text format     Abstract available

  10. RUTKOVSKY AC, Yeh ES, Guest ST, Findlay VJ, et al
    Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    BMC Cancer. 2019;19:491.
    PubMed     Text format     Abstract available


    Br J Cancer

  11. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
    Night shift work and risk of breast cancer in women: the Generations Study cohort.
    Br J Cancer. 2019 May 29. pii: 10.1038/s41416-019-0485.
    PubMed     Text format     Abstract available


    Breast Cancer

  12. HAO R, Liu Y, Du Q, Liu L, et al
    Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome.
    Breast Cancer. 2019 May 29. pii: 10.1007/s12282-019-00981.
    PubMed     Text format     Abstract available

  13. MANFUKU M, Nishigami T, Mibu A, Tanaka K, et al
    Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls.
    Breast Cancer. 2019 May 24. pii: 10.1007/s12282-019-00979.
    PubMed     Text format     Abstract available

  14. MASUDA N, Mukai H, Inoue K, Rai Y, et al
    Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Breast Cancer. 2019 May 24. pii: 10.1007/s12282-019-00970.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  15. LEE E, Nelson OL, Puyana C, Takita C, et al
    Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study.
    Breast Cancer Res. 2019;21:70.
    PubMed     Text format     Abstract available

  16. QUINTELA-FANDINO M, Apala JV, Malon D, Mouron S, et al
    Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
    Breast Cancer Res. 2019;21:69.
    PubMed     Text format     Abstract available

  17. ROSSI L, Biagioni C, McCartney A, Migliaccio I, et al
    Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
    Breast Cancer Res. 2019;21:71.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  18. LAMBERTINI M, Campbell C, Gelber RD, Viale G, et al
    Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
    Breast Cancer Res Treat. 2019 May 27. pii: 10.1007/s10549-019-05284.
    PubMed     Text format     Abstract available

  19. ENGMANN NJ, Scott CG, Jensen MR, Winham S, et al
    Combined effect of volumetric breast density and body mass index on breast cancer risk.
    Breast Cancer Res Treat. 2019 May 25. pii: 10.1007/s10549-019-05283.
    PubMed     Text format     Abstract available

  20. DONG B, Xie C, Jing X, Lin L, et al
    Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05278.
    PubMed     Text format     Abstract available

  21. SAW S, Lim J, Lim SH, Wong M, et al
    Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05290.
    PubMed     Text format     Abstract available

  22. BASULAIMAN B, Awan AA, Fergusson D, Vandermeer L, et al
    Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05274.
    PubMed     Text format     Abstract available

  23. ROSENBERG SM, Vaz-Luis I, Gong J, Rajagopal PS, et al
    Employment trends in young women following a breast cancer diagnosis.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05293.
    PubMed     Text format     Abstract available

  24. KRYSTEL-WHITTEMORE M, Xu J, Brogi E, Ventura K, et al
    Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2019 May 29. pii: 10.1007/s10549-019-05295.
    PubMed     Text format     Abstract available

  25. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05285.
    PubMed     Text format     Abstract available

  26. PINEDA-MONCUSI M, Servitja S, Tusquets I, Diez-Perez A, et al
    Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05289.
    PubMed     Text format     Abstract available


    Breast J

  27. NGUI NK, Hitos K, Hughes TMD
    Effect of the American College of Surgeons Oncology Group Z0011 trial on axillary management in breast cancer patients in the Australian setting.
    Breast J. 2019 May 27. doi: 10.1111/tbj.13343.
    PubMed     Text format     Abstract available

  28. ABDEL-RAHMAN O
    Outcomes of metastatic breast cancer patients in relationship to disease-free interval following primary treatment of localized disease; a pooled analysis of two clinical trials.
    Breast J. 2019 May 27. doi: 10.1111/tbj.13346.
    PubMed     Text format     Abstract available

  29. MOUSAVI M, Zargan J, Haji Noor Mohammadi A, Goudarzi HR, et al
    Anticancer effects of the Latrodectus dahli crude venom on MCF-7 breast cancer cell line.
    Breast J. 2019 May 26. doi: 10.1111/tbj.13332.
    PubMed     Text format    

  30. PRINSLOO S, Rebello E, Cata JP, Black D, et al
    Electroencephalographic correlates of hypnosedation during breast cancer surgery.
    Breast J. 2019 May 24. doi: 10.1111/tbj.13328.
    PubMed     Text format    


    Cancer Lett

  31. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  32. MAGBANUA MJM, Yau C, Wolf DM, Lee JS, et al
    Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predict adverse outcome in early breast cancer.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3888.
    PubMed     Text format     Abstract available

  33. LI Q, Guan X, Chen S, Yi Z, et al
    Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Clin Cancer Res. 2019 May 28. pii: 1078-0432.CCR-18-4173.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  34. SORRENTINO L, Regolo L, Scoccia E, Petrolo G, et al
    Autologous fat transfer after breast cancer surgery: An exact-matching study on the long-term oncological safety.
    Eur J Surg Oncol. 2019 May 21. pii: S0748-7983(19)30451.
    PubMed     Text format     Abstract available

  35. SAVOLT A, Cserni G, Lazar G, Maraz R, et al
    Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Eur J Surg Oncol. 2019 May 16. pii: S0748-7983(19)30454.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  36. YANG Y, Wu L, Shu XO, Cai Q, et al
    Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent.
    J Natl Cancer Inst. 2019 May 29. pii: 5505447. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Oncol

  37. DAS M
    GM1 for taxane-induced neuropathy in breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30373.
    PubMed     Text format    

  38. STIRRUPS R
    Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30372.
    PubMed     Text format    


    Pathology

  39. ZABOROWSKI M, Pearson A, Sioson L, Gill AJ, et al
    Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?
    Pathology. 2019;51:327-329.
    PubMed     Text format    

  40. WANG M, McLaren S, Jeyathevan R, Allanson BM, et al
    Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance.
    Pathology. 2019;51:246-252.
    PubMed     Text format     Abstract available

  41. DESSAUVAGIE BF, Thomas C, Robinson C, Harvey J, et al
    Digital evaluation of proliferative 'hotspots' of more than 16,000 cells negatively impacts Ki-67 assessment in breast carcinoma.
    Pathology. 2019;51:329-331.
    PubMed     Text format    


    PLoS Genet

  42. DEASY SK, Uehara R, Vodnala SK, Yang HH, et al
    Aicardi-Goutieres syndrome gene Rnaseh2c is a metastasis susceptibility gene in breast cancer.
    PLoS Genet. 2019;15:e1008020.
    PubMed     Text format     Abstract available


    PLoS One

  43. SALEH ME, Gadalla R, Hassan H, Afifi A, et al
    The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients.
    PLoS One. 2019;14:e0217550.
    PubMed     Text format     Abstract available

  44. RATH M, Li Q, Li H, Lindstrom S, et al
    Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients.
    PLoS One. 2019;14:e0216997.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  45. Correction for Kroger et al., Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells.
    Proc Natl Acad Sci U S A. 2019 May 28. pii: 1907473116.
    PubMed     Text format    

  46. BAI J, Wu K, Cao MH, Yang Y, et al
    SCF(FBXO22) targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.
    Proc Natl Acad Sci U S A. 2019 May 28. pii: 1820990116.
    PubMed     Text format     Abstract available


    Radiology

  47. EBY PR
    Breast Cancer: Let Imaging Be Our Guide and Improving Patient Outcomes Be Our Goal.
    Radiology. 2019 May 28:190949. doi: 10.1148/radiol.2019190949.
    PubMed     Text format    

  48. ROSENBERG RD, Seidenwurm D
    Optimizing Breast Cancer Screening Programs: Experience and Structures.
    Radiology. 2019 May 28:190924. doi: 10.1148/radiol.2019190924.
    PubMed     Text format    

  49. HA SM, Cha JH, Shin HJ, Chae EY, et al
    Mammography, US, and MRI to Assess Outcomes of Invasive Breast Cancer with Extensive Intraductal Component: A Matched Cohort Study.
    Radiology. 2019 May 28:182762. doi: 10.1148/radiol.2019182762.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: